Prothena Corporation plc
Prothena Corp plc (Form: 8-K, Received: 03/03/2014 16:13:39)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K  
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 1, 2014
_______________________________________________________
Prothena Corporation plc
(Exact Name of Registrant as Specified in its Charter)
_______________________________________________________
Ireland
(State or Other Jurisdiction of Incorporation)
 
 
 
001-35676
 
98-1111119
(Commission
File Number)
 
(IRS Employer
Identification No.)
650 Gateway Boulevard
South San Francisco, California 94080
(Address of Principal Executive Offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 837-8550
______________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On March 3, 2014, Prothena Corporation plc (the “Company”) announced the promotion of Tara Nickerson, PhD, MBA, from Head of Corporate and Business Development to Chief Business Officer of the Company, effective March 1, 2014.

In connection with the promotion, Dr. Nickerson will be entitled to severance benefits under the Company’s Amended and Restated Severance Plan at a level equal to Tier 1 (Leadership I) and her base salary will also be increased to $300,000. Dr. Nickerson’s other compensation arrangements with the Company will remain unchanged.

The foregoing descriptions of the material terms of Dr. Nickerson’s benefits changes are qualified in their entirety by the terms of a promotion letter filed as Exhibit 10.1 to this report and incorporated by reference herein.

Item 9.01.
Financial Statements and Exhibits.
(d)  Exhibits .
Exhibit No.
 
Description
10.1
 
Tara Nickerson Promotion Letter.    



2




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2014
PROTHENA CORPORATION PLC
 
 
 
 
 
By:
 
/s/ Tran B. Nguyen
 
Name:
 
Tran B. Nguyen
 
Title:
 
Chief Financial Officer


3




EXHIBIT INDEX
 
Exhibit No.
 
Description
10.1
 
Tara Nickerson Promotion Letter.    


4



Exhibit 10.1

February 5, 2014


Tara Nickerson


Tara -
I am very pleased to inform you of your promotion to Chief Business Officer , effective March 1, 2014. In this new role, we expect that you will contribute significantly to the advancement of our business and achievement of our goals in 2014 and beyond.
In addition to the change in title and responsibilities, your promotion may impact certain of Prothena’s compensation and benefits plans:
Your annual bonus opportunity under the Prothena Corporation plc Incentive Compensation Plan will remain 40% of annual salaried-earnings
Your Tier level under the Prothena Biosciences Inc Amended and Restated Severance Plan moves from Tier 2 (Leadership II) to Tier 1 (Leadership I) - further details are attached

On behalf of the Board of Directors and Leadership Team, I thank you for the work you’ve put in to earn this promotion, and I look forward to your continued success here at Prothena.

Sincerely,

/s/ Dale B. Schenk
Dale B. Schenk
President and Chief Executive Officer





Your employment remains “at will.” This means that you and Prothena each have the right to terminate the employment relationship at any time, with or without cause. Nothing in this letter should be taken as a guarantee of continued employment or a specific term of employment.